Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study

Cecchi, Rossana; Muciaccia, Barbara; Ciallella, Costantino; Luca, Natale Mario di; Kimura, Akihiko; Sestili, Cristina; Nosaka, Mizuho; Kondo, Toshikazu

doi:10.1007/s00414-017-1589-3

Cited by 20 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, we reported reduced left ventricular ejection fractions and ventricular diastolic impairments in middle-aged long-term users of supraphysiologic-dose AAS (Baggish et al, 2010), effects that we and others confirmed in subsequent larger-scale studies (Angell et al, 2012;Luijkx et al, 2013;Baggish et al, 2017;Rasmussen et al, 2018a). Other groups also have reported finding right ventricular abnormalities (Angell et al, 2014;Alizade et al, 2016;Rasmussen et al, 2018a), apoptosisrelated fibrotic changes in the heart (Cecchi et al, 2017), increased systolic blood pressure and aortic stiffness (Rasmussen et al, 2018b), and a pro-coagulant state (Chang et al, 2018) in long-term supraphysiologic-dose AAS users. In an echocardiography study in male rabbits, 6 months of supraphysiologic nandrolone administration (SC, 4 or 10 mg/kg, twice/ week) was associated with impaired global myocardial performance in a dose-related manner (Vasilaki et al, 2016).…”

Section: Cardiovascular Abnormalities Associated With Supraphysiologisupporting

confidence: 78%

Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?

Kaufman

Kanayama

Hudson

et al. 2019

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Supraphysiologic-dose anabolic-androgenic steroid (AAS) use is associated with physiologic, cognitive, and brain abnormalities similar to those found in people at risk for developing Alzheimer's Disease and its related dementias (AD/ADRD), which are associated with high brain β-amyloid (Aβ) and hyperphosphorylated tau (tau-P) protein levels. Supraphysiologic-dose AAS induces androgen abnormalities and excess oxidative stress, which have been linked to increased and decreased expression or activity of proteins that synthesize and eliminate, respectively, Aβ and tau-P. Aβ and tau-P accumulation may begin soon after initiating supraphysiologic-dose AAS use, which typically occurs in the early 20s, and their accumulation may be accelerated by other psychoactive substance use, which is common among non-medical AAS users. Accordingly, the widespread use of supraphysiologic-dose AAS may increase the numbers of people who develop dementia. Early diagnosis and correction of sex-steroid level abnormalities and excess oxidative stress could attenuate risk for developing AD/ADRD in supraphysiologic-dose AAS users, in people with other substance use disorders, and in people with low sex-steroid levels or excess oxidative stress associated with aging.

show abstract

Section: Cardiovascular Abnormalities Associated With Supraphysiologisupporting

confidence: 78%

Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?

Kaufman

Kanayama

Hudson

et al. 2019

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

show abstract

“…Also, Montisci et al found left ventricular hypertrophy in four autopsies and even an association with fibrosis, myocytolysis, and drug-induced eosinophilic myocarditis [29]. Cecchi et al discovered a direct apoptotic cardiac and endothelial change in the heart tissue of deceased patients with heart failure who had a history of AS abuse [30]. In 2003, Hartgens et al conducted two echocardiographic studies over a period of 8-16 weeks in 17 AS users and 15 non-users [31].…”

Section: Cardiomyopathy and Asmentioning

confidence: 99%

Anabolic Steroids and Cardiovascular Outcomes: The Controversy

Perry¹,

Schuetz²,

Memon³

et al. 2020

Cureus

View full text Add to dashboard Cite

Anabolic steroids (AS) are synthetic derivatives of the male sex hormone testosterone. The use of AS is not limited to bodybuilders and athletes, but non-athletes also use them. It is used to enhance athletic performance, induce muscle hypertrophy, and augment male sexual characteristics. AS use is associated with a wide range of side effects and potential cardiovascular complications. In this article, we have searched the available literature to investigate the association between AS use and cardiovascular disease (CVD). The results revealed that AS was linked to lipid metabolism derangements, hypertension, coagulation disorders, and cardiomyopathy. We concluded, based on the relevant data, that there was evidence that suggests an association with CVD, primarily myocardial infarction, fatal arrhythmias, and cardiomyopathy in AS users. The general population should be informed of the risk. Also, methods of primary and secondary prevention should be implemented to mitigate the risk of CVD secondary to AS.

show abstract

“…AAS is associated with myocardial apoptosis. [48] In an animal model, ventricular myocytes were isolated from adult male rabbits and treated in vitro for 20 h using different doses of STZ, Testosterone Enanthate (TE), and Testosterone (T) (0.1, 1, 10, and 100 μmol/L). These results showed, for the first time, that AASs induce significant myocardial apoptosis in a dose-dependent manner.…”

Section: Effects Of Aas On the Cardiovascular Systemmentioning

confidence: 99%

Anabolic-androgenic steroids and cardiovascular risk

Liu

2019

Chinese Medical Journal

View full text Add to dashboard Cite

Objective:Anabolic-androgenic steroids (AAS) represents a group of synthetic testosterone derivatives that play an important role in clinical treatment. These drugs are widely abused among the general public to increase lean weight and improve athletic performance. It has been reported that AAS use can produce many adverse effects, especially the occurrence of cardiovascular risk. Although there are many related studies, there has been no consensus on AAS use and cardiovascular risk. The present study was to review the effect of AAS on the cardiovascular system.Data sources:The data in this review were obtained from articles included in PubMed and the National Center for Biotechnology Information database.Study selection:Original articles, case reports, and systematic reviews about AAS were selected for the article.Results:The use/abuse of AAS is correlated with higher cardiovascular risks, and many AAS users/abusers had cardiovascular diseases. However, there are many confounding factors in the studies that explored the causality between AAS intake and disease development, and additional studies are required to determine AAS toxicity.Conclusion:AAS produces toxic effects on the cardiovascular system, and it is necessary to ensure that more people know this about AAS, including medical personnel.

show abstract

Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study

Cited by 20 publications

References 34 publications

Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?

Supraphysiologic-dose anabolic–androgenic steroid use: A risk factor for dementia?

Anabolic Steroids and Cardiovascular Outcomes: The Controversy

Anabolic-androgenic steroids and cardiovascular risk

Contact Info

Product

Resources

About